Quick Answer
GALECTIN THERAPEUTICS INC reported Operating Income Loss of -$20.09 million for the year ending 2025.
- GALECTIN THERAPEUTICS INC showed an increase of +52.7% in Operating Income Loss from 2024 to 2025.
- This data is from GALECTIN THERAPEUTICS INC's annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), GALECTIN THERAPEUTICS INC's Operating Income Loss has declined by 311.3%.
- Historical annual values: Fiscal year 2025: -$20.09 million | Fiscal year 2024: -$42.43 million | Fiscal year 2023: -$38.07 million | Fiscal year 2022: -$38.35 million | Fiscal year 2021: -$30.18 million | Fiscal year 2020: -$23.44 million | Fiscal year 2019: -$13.44 million | Fiscal year 2018: -$13.60 million | Fiscal year 2017: -$16.25 million | Fiscal year 2016: -$21.48 million | Fiscal year 2015: -$20.08 million | Fiscal year 2014: -$15.43 million | Fiscal year 2013: -$12.10 million | Fiscal year 2012: -$9.90 million | Fiscal year 2011: -$10.41 million | Fiscal year 2010: -$4.88 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: